BRAF and neoplasm: Beside the effect on the biological target and pathway, there is strong evidence that the therapeutic efficacy of BRAFi and MEKi relies on additional factors involved in tumor-host interactions and preclinical data show that oncogenic BRAF contributes to immune evasion, as targeting this mutation may increase melanoma immunogenicity [8].